Cocaine Abuse and ADHD - 10

This study has been completed.
Sponsor:
Collaborator:
New York State Psychiatric Institute
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000275
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: November 1996
  Purpose

The purpose of this study is to evaluate the safety and efficacy of buproprion in treating individuals with adult attention-deficit hyperactivity disorder (ADHD) and cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Flupenthixol
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Cocaine Abuse and ADHD

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Drug use
  • Cocaine craving
  • ADHD symptoms
  • Improvement in functioning
  • Tolerability

Estimated Enrollment: 16
Study Start Date: November 1996
Estimated Study Completion Date: March 1998
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000275

Locations
United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
New York State Psychiatric Institute
Investigators
Principal Investigator: Herbert Kleber, M.D. New York State Psychiatric Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000275     History of Changes
Other Study ID Numbers: NIDA-09236-10, P50-09236-10
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Flupenthixol
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014